SEARCH

SEARCH BY CITATION

References

  • 1
    Fox CB. Squalene emulsions for parenteral vaccine and drug delivery. Molecules 2009; 14:3286312.
  • 2
    Yang YW, Wu CA, Morrow WJW. Cell death induced by vaccine adjuvants containing surfactants. Vaccine 2004; 22:152436.
  • 3
    Fox CB, Baldwin SL, Duthie MS, Reed SG, Vedvick TS. Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsions. Vaccine 2011; 29:956372.
  • 4
    Fox CB, Baldwin SL, Duthie MS, Reed SG, Vedvick TS. Immunomodulatory and physical effects of phospholipid composition in vaccine adjuvant emulsions. AAPS Pharm Sci Tech 2012; 13:498506.
  • 5
    Frey A, Di Canzio J, Zurakowski D. A statistically defined endpoint titer determination method for immunoassays. J Immunol Methods 1998; 221:3541.
  • 6
    Hibbert DB, Gooding JJ. Data Analysis for Chemistry. New York: Oxford University Press, 2006.
  • 7
    Strickley RG. Solubilizing excipients in oral and injectable formulations. Pharm Res 2004; 21:20130.
  • 8
    U.S. Food and Drug Administration. Inactive Ingredient Search for Approved Drug Products [database on the Internet]. U.S. Food and Drug Administration. Available at http://www.accessdata.fda.gov/scripts/cder/iig/index.cfm (Accessed August 8, 2012).
  • 9
    Baldwin SL, Shaverdian N, Goto Y et al. Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion. Vaccine 2009; 27:595663.
  • 10
    Lousada-Dietrich S, Jogdand PS, Jepsen S et al. A synthetic TLR4 agonist formulated in an emulsion enhances humoral and Type 1 cellular immune responses against GMZ2 - a GLURP-MSP3 fusion protein malaria vaccine candidate. Vaccine 2011; 29:328492.
  • 11
    Massey JB, Pownall HJ. Interaction of α-tocopherol with model human high-density lipoproteins. Biophys J 1998; 75:292331.
  • 12
    Fox CB, Anderson RC, Dutill TS, Goto Y, Reed SG, Vedvick T. Monitoring the effects of component structure and source and formulation stability and adjuvant activity of oil-in-water emulsions. Coll Surf B: Bioint 2008; 65:98105.
  • 13
    Yang YW, Wei AC, Shen SS. The immunogenicity-enhancing effect of emulsion vaccine adjuvants is independent of the dispersion type and antigen release rate--a revisit of the role of the hydrophile-lipophile balance (HLB) value. Vaccine 2005; 23:266575.
  • 14
    Relas H, Gylling H, Miettinen TA. Fate of intravenously administered squalene and plant sterols in human subjects. J Lipid Res 2001; 42:98894.
  • 15
    Ball MJ. Hematological and biochemical effects of parenteral nutrition with medium chain triglycerides: comparison with long-chain triglycerides. Am J Clin Nutr 1991; 53:91622.
  • 16
    Rossi J, Leroux JC. Principles in the development of intravenous lipid emulsions; in Wasan KM (ed.): Role of Lipid Excipients in Modifying Oral and Parenteral Drug Delivery. Hoboken, NJ: John Wiley & Sons Inc., 2006; 88123.
  • 17
    Yeh SL, Chao CY, Lin MT, Chen WJ. Effects of parenteral infusion with medium-chain triglycerides and safflower oil emulsions on hepatic lipids, plasma amino acids and inflammatory mediators in septic rats. Clin Nutr 2000; 19:11520.
  • 18
    Sasol. Miglyol Product Information. Available at http://www.sasoltechdata.com/tds/miglyols.pdf (Accessed 17 December 2007).
  • 19
    Available at http://www.chemspider.com (Accessed 8 August 2012).
  • 20
    Jansen T, Hofmans MPM, Theelen MJG, Manders F, Schijns VEJC. Structure- and oil type-based efficacy of emulsion adjuvants. Vaccine 2006; 24:54005.
  • 21
    Jansen T, Hofmans MPM, Theelen MJG, Schijns VEJC. Structure-activity relations of water-in-oil vaccine formulations and induced antigen-specific antibody responses. Vaccine 2005; 23:105360.
  • 22
    Morel S, Diderlaurent A, Bourguignon P et al. Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 2011; 29:246173.